Generex Subsidiary Antigen Express To Present At Prestigious Cancer Immunotherapy Summit

WORCESTER, Mass. and TORONTO, Feb. 27, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT.OB) announced today that Dr. Eric von Hofe, Ph.D., President of Generex subsidiary Antigen Express, Inc., will give a presentation at the upcoming Cancer Immunotherapy Summit to be held in Boston, MA February 27-29.  The presentation, entitled "Recent Advances in Understanding the Immune System and the Role of Th cells," will be given Wednesday, February 29 at 9:45 am EST. 

The presentation will focus on technology pioneered by Antigen Express scientists to develop compounds that provide specific T helper (Th) cell activation in cancer immunotherapy as well as clinical trials of those compounds.  In particular, it has been shown that this cell type plays a central role in multiple aspects of cancer immunotherapy.  The Company has developed a peptide-based technology to potently and specifically activate this cell type to produce a robust immune response.

The Company recently announced positive interim results from a randomized Phase II trial of one of its compounds, AE37, in patients with breast cancer.  Specifically, Kaplan Meier projections showed a disease-free survival in low HER2 expressing patients of 88.6% in the treated group versus 71.9% in the control arm.  Given these results, the Company announced plans for an end of Phase II meeting with the FDA by the middle of the year.  Immediately following that meeting, the Company will begin the process for submission of a Special Protocol Assessment for a Phase III trial.

About AE37 and Ii-Key Hybrid Platform Technology

Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for large, unmet medical needs.  The Company's Ii-Key Hybrid technology platform entails the modification of fragments of antigens to increase their potency in stimulating critical members of the immune response, known as CD4+ T helper cells. Incorporating the Ii-Key modification along with tumor-associated antigens can greatly enhance the immune system's ability to recognize and destroy cancer cells bearing any of the targeted antigens as well as increasing immunological memory.

1 2 3 4 Next › Last »